Why Dermata Therapeutics Stock Took Off After-Hours
Why Dermata Therapeutics Stock Took Off After-Hours
Dermata Therapeutics, Inc. (NASDAQ:DRMAW) shares are trading higher in Thursday's after-hours session after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis.
Dermata Therapeutics, Inc.（納斯達克股票代碼：DRMAW）股價在週四盤後交易中走高，此前該公司宣佈爲其治療多汗症的 DMT410 計劃在日本發放一項新專利。
What To Know: The announcement of the patent was made Thursday after market close, making it Dermata's first patent issued for DMT410.
須知：該專利是在週四收盤後宣佈的，這使它成爲Dermata爲DMT410 頒發的第一項專利。
The program leverages the company's Spongilla technology to topically deliver botulinum toxin in treating the condition.
該計劃利用該公司的Spongilla技術局部輸送肉毒桿菌毒素來治療該疾病。
It was also noted there are talks of partnership prospects that would further the development of DMT410.
還有人指出，關於夥伴關係前景的討論將進一步推動 DMT410 的發展。
"We believe this patent issuance further validates DMT410's novel concept to easily deliver botulinum toxin topically instead of requiring patients to receive multiple injections," said Gerry Proehl, Dermata's chairman, president and CEO.
Dermata董事長、總裁兼首席執行官Gerry Proehl表示：“我們認爲，本次專利的頒發進一步驗證了 DMT410 的新概念，即可以輕鬆地局部輸送肉毒毒素，而不是要求患者接受多次注射。”
"We are excited about the opportunities the DMT410 program can bring to patients, not only for the treatment of axillary hyperhidrosis as we have seen in our proof-of-concept study, but potentially for palmer and plantar hyperhidrosis which has no currently approved products," he added.
他補充說：“我們對 DMT410 計劃能夠爲患者帶來的機會感到興奮，這不僅是我們在概念驗證研究中看到的腋窩多汗症的治療，而且可能用於治療目前尚無批准產品的帕爾默和足底多汗症。”
Related Link: Why Tradeweb Markets Stock Is Moving
相關鏈接：爲什麼 Tradeweb Markets 股票走勢
DRMA Price Action: Shares of Dermata were up 96.7% at $1.20 in the after-hours session at the time of publication, according to Benzinga Pro.
DRMA價格走勢：根據Benzinga Pro的數據，Dermata的股價在發佈時的盤後交易中上漲了96.7％，至1.20美元。
Photo: Steve Buissinne from Pixabay
照片：來自 Pixabay 的 Steve Buissinne
譯文內容由第三人軟體翻譯。